There are 2185 resources available
520P - Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Presenter: Rocio Garcia-Carbonero
Session: Poster session 15
Resources:
Abstract
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
Resources:
Abstract
521P - XELOX +bev +tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
Presenter: Kai Ou
Session: Poster session 15
Resources:
Abstract
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
Resources:
Abstract
522P - Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)
Presenter: Kazuhiro Shiraishi
Session: Poster session 15
Resources:
Abstract
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18
Resources:
Abstract
523P - A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Presenter: Munehiro Wakabayashi
Session: Poster session 15
Resources:
Abstract
1927P - AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study
Presenter: Feng Shi
Session: Poster session 18
Resources:
Abstract
524P - A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Presenter: Ahreum Lim
Session: Poster session 15
Resources:
Abstract
1928P - Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): A prospective, open-label, phase II study
Presenter: Jun Cao
Session: Poster session 18
Resources:
Abstract